GSK reports H5N1 data, updates pipeline

GlaxoSmithKline (LSE:GSK; GSK) reported positive results from a Phase I trial of its H5N1 pandemic influenza vaccine, as well as a number of pipeline updates. Interim data from the observer-blind, Belgian Phase I study of the inactivated H5N1 virus vaccine in 400 healthy volunteers showed that 80% of those receiving the vaccine had a strong seroprotective immune response. Final results are expected in October. The vaccine also is in an international Phase III trial in 5,000 volunteers, with data and regulatory filing expected by year end.

Also, GSK started Phase III trials of Redona denagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor for Type II diabetes; and of rosiglitazone XR for Alzheimer's disease. GSK markets the PPAR gamma agonist Avandia rosiglitazone for diabetes. The company also discontinued Phase II testing of radafaxine for depression due to an unfavorable risk/benefit assessment. Radafaxine is a noradrenaline and dopamine reuptake inhibitor. ...